MADISON, Wis. – BioSystem Development, creator of the AssayMAP® microchromatography technology, announces the recent closure of a fully-subscribed fundraising round, raising just over 1 million dollars (USD). A total of $750,000 of new equity was raised from individual angel investors and a loan from the Madison Development Corporate Venture Debt Fund contributed $300,000. The proceeds will be used to scale up the company’s manufacturing capabilities, increase the speed to market for new products and support pipeline expansion. Founder and Chief Executive Officer Scott Fulton stated, “We are pleased to close the round. This funding allows us to respond to increased demand from our strategic partners.” This demand is in part created by the launch of the AssayMAP Bravo® system, a fully automated high-throughput instrument co-developed with Agilent Technologies.

About BioSystem Development: BioSystem Development, established in 2002, creates, manufactures and markets tools and products to meet the critical and growing analytical needs of pharmaceutical development. The company’s AssayMAP platform, based on disposable micro?chromatography cartridges and automation, enables high throughput solutions for bioprocess development, biomarkers and general life science research that reduce development time and increase efficiency. For more information about AssayMAP technology, visit www.AssayMAP.com. AssayMAP® is patented technology and registered trademark of BioSystem Development.